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Abstract
Cell-free and concentrated ascites reinfusion therapy (CART) is an effective therapy 
for refractory ascites. However, CART is difficult to perform as ascites filtration 
and concentration is a complicated procedure. Moreover, the procedure requires the 
constant assistance of a clinical engineer or/and the use of an expensive equipment 
for the multi-purpose blood processing. Therefore, we developed a CART special-
ized equipment (mobility CART [M-CART]) that could be used safely with various 
safety measures and automatic functions such as automatic washing of clogged filtra-
tion filter and self-regulation of the concentration ratio. Downsizing, lightning of the 
weight, and automatic processing in M-CART required the use of newly developed 
multi-ring-type roller pump units. This equipment was approved under Japanese reg-
ulations in 2018. In performing 41 sessions of CART (for malignant ascites, 22 ses-
sions; and hepatic ascites, 19 sessions) using this equipment in 17 patients, no serious 
adverse event occurred. An average of 4494 g of ascites was collected and the total 
amount of ascites was processed in all the sessions without any trouble. The mean 
weight of the processed ascites was 560 g and the mean concentration ratio was 8.0. 
The ascites were processed at a flow rate of 50 mL/min. The mean ascites processing 
time was 112.5 minutes and a 106.5-minutes (95.2%) ascites processing was per-
formed automatically. The operator responded to alarms or support information 3.2 
times on average (3.1 minutes, 2.1% of ascites processing time). Human errors related 
to ascites processing were detected by M-CART at 0.4 times per session on aver-
age and were appropriately addressed by the operator. The frequencies of automatic 
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1 |  INTRODUCTION
Cell-free and concentrated ascites reinfusion therapy 
(CART) is the treatment for refractory ascites, which resulted 
from a disease such as advanced cancer or liver cirrhosis.1-3 
CART was approved in Japan in 1981 by the National Health 
Insurance and was initially performed in patients with he-
patic ascites caused by liver cirrhosis.4,5 Recently, CART 
has been widely performed in patients with malignant ascites 
and more than 85% of patients who underwent CART had 
malignant ascites as reported in the post-marketing surveil-
lance.6 CART comprises three processes: (a) drainage pro-
cess, which involves the collection of ascites by paracentesis; 
(b) filtration and concentration process, which involves the 
complete removal of cell components and bacteria using a 
filtration filter and removal of superabundant water using a 
concentration filter; and (c) treated ascitic intravenous drip 
infusion process. CART is effective for the relief of symp-
toms and prevents the worsening of nutritional status through 
the drainage of ascites.6-9 Furthermore, the use of a combi-
nation of chemotherapy and CART10 and the application of 
sampling cells to cancer vaccines11 were reported, and CART 
was recognized as an effective treatment that can support 
cancer therapy.
The ascites processing in CART had been performed 
using a drop-type method,12 an aspiration-type method 
(KM-CART),13 a pump-type method using the roller pump 
equipment without the mode for CART,14,15 a combination of 
these methods (eg, DC-CART),16 and a pump-type method 
using the expensive multi-purpose blood processing equip-
ment with the mode for CART.5 At the priming phase, the 
filtration filter must be checked for any leaks to prevent the 
contamination of cancer cells or bacteria by the corruption of 
the hollow fiber.17 Using the multi-purpose blood process-
ing equipment with the mode for CART, this leak check is 
automatically carried out, but is performed in other methods 
manually. When the filtration filter is clogged, reduction of 
filtration flow, drainage of the clogging substances in the 
Tokushima University Hospital, 
Tokushima, Japan
10Dialysis Center, Shikoku Central Hospital 
of the Mutual Aid Association of Public 
School Teachers, Shikokuchuo, Japan
11Department of Gastroenterology, 
Tokushima Prefectural Central Hospital, 
Tokushima, Japan
12Department of Gastroenterology, 
Yoshinogawa Medical Center, 
Yoshinogawa, Japan
13Department of Internal Medicine, Tsurugi 
Municipal Handa Hospital, Tsurugi, Japan
14Department of Internal Medicine, 
Tokushima Municipal Hospital, 
Tokushima, Japan
15Medical Device Business Division, 
Takatori Corporation, Kashihara, Japan
Correspondence
Toshiya Okahisa, Department of General 
Medicine and Community Health 
Science, Institute of Biomedical Sciences, 
Tokushima University Graduate School, 




Japan Agency for Medical Research and 
Development, Grant/Award Number: 
25-017; Ministry of Economy, Trade and 
Industry, Grant/Award Number: 25-017; 
New Energy and Industrial Technology 
Development Organization, Grant/Award 
Number: 27J1130; Takatori Corporation
washing of clogged filtration filter and self-regulation of the concentration ratio were 
31.7% and 53.7%, respectively. The mean recovery rates (recovery dose) of protein, 
albumin, and immunoglobulin G were 72.9%, 72.9%, and 71.2% (65.9 g, 34.9 g, and 
13.2 g), respectively. Steroids were administered in 92.7% of the sessions to prevent 
fever and the mean increase in body temperature was 0.53°C. M-CART is a compact 
and lightweight automatic CART specialized equipment that can safely and easily 
process a large quantity of ascites without the constant assistance of an operator.
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hollow fibers, or manual washing of filter with normal sa-
line using a syringe was performed.13 However, clogging of 
the filtration or concentration filters sometimes prevented the 
processing of the entire volume of collected ascites.6,15
Therefore, we developed a novel CART specialized equip-
ment that could process a large quantity of ascites safely and 
automatically without requiring the constant assistance of 
an operator by improving the automatic functions and safety 
measures. In this study, we aimed to report the course of the 
development, structure, and characteristics of the developed 
equipment; usability at priming; and the clinical evaluations 
that involved the performance of CART in 41 sessions.
2 |  MATERIALS AND METHODS
2.1 | Development project
We built a consortium consisting of Tokushima University, 
Tokushima University Hospital, a medium-sized manufac-
turing company (Takatori Corporation, Nara, Japan), and 
affiliated hospitals to develop a novel CART specialized 
equipment and established a research and development room 
in the incubation center (Fujii Memorial Institute of Medical 
Sciences) inside the Tokushima University Hospital prem-
ises. Initially, we developed a CART specialized equipment 
(tractable CART [T-CART]), which could be used easily, 
while being adopted by the Program to Support Development 
of Medical Equipment and Devices to Solve Unmet Medical 
Needs (Grant No. 25-017, fiscal year 2013, Ministry of 
Economy, Trade and Industry [METI]) and Development of 
Medical Device through Collaboration between Medicine 
and Industry (Grant No. 25-017, fiscal year 2014-2015, Japan 
Agency for Medical Research and Development [AMED]). 
Through the accompanying consultation of these projects, we 
received continuous advice on commercialization by experts 
from various fields.
During the course of the development, the introduction of 
the design thinking using the Dialogue Tools for Innovation 
(Seeds and Needs Creation Reinforcement Support Project in 
Universities, fiscal year 2014, Ministry of Education, Culture, 
Sports, Science and Technology) was connected to a novel 
idea to perform all automatic processes, from priming to the 
filtration and concentration, using only one pump unit and led 
to the development of the multi-ring-type roller pump unit 
(Mediation Research and Development Promotion Business 
to Backbone, the Small and Medium-sized Enterprise, 
Grant No. 27J1130, fiscal year 2015-2016, New Energy and 
Industrial Technology Development Organization [NEDO]). 
T-CART was improved after the introduction of this pump 
unit and a downsized lightweight low price model (mobility 
CART [M-CART]) was completed (Figure 1). M-CART was 
approved under Japanese regulations in March 2018 and was 
released in December 2018.
2.2 | Multi-ring-type roller pump unit
The multi-ring-type roller pump unit has more than two roller 
heads, each equipped with one-way clutch, and is driven with 
F I G U R E  1  Developed CART 
specialized equipment. T-CART was 
improved by introducing the multi-ring-
type roller pump unit and a compact CART 
specialized equipment (M-CART) was 
completed. In M-CART, 70% downsizing 
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one motor (Figure 2A). The one-way clutch is a clutch that 
conveys a torsional force toward a single direction. The roller 
heads turn according to the direction of the rotational axis 
and the roller head that does not turn is referred to as the 
clamp. M-CART is equipped with two multi-ring-type roller 
pump units (Figure 2B). Each roller pump is equipped with 
two roller heads arranged with the upper clockwise-rotation 
roller head above the lower counterclockwise-rotation roller 
head. When the rotational axis of the pump is rotated clock-
wise, only the upper roller head rotates, and when rotated 
counterclockwise, only the lower roller head rotates.
2.3 | M-CART
M-CART is equipped with two multi-ring-type roller pump 
units (two motors), three pressure monitors, two electric clamps, 
one air detector, two filter holders, and two removable poles 
(Figure 2B). In M-CART, 70% downsizing and 60% lightning 
of the weight were achieved by introducing two multi-ring-type 
roller pump units into the T-CART, whose size was almost the 
same as that of the existing equipment (Figure 1).
Various automatic processes, including the response to 
clogging of the filtration and concentration filters (auto-
matic washing of clogged filtration filter with normal sa-
line and self-regulation of the concentration ratio), were 
enabled (Table 1). Figures 3 and 4, respectively, present the 
photograph and circuit of M-CART. The negative pressure 
driving force is produced by the left-side upper pump lo-
cated between the filtration and concentration filters in the 
tube circuit (Figure 4A). Ascites is filtrated from inside the 
hollow fibers to outside in the filtration filter. The left-side 
upper pump also produces a positive pressure force to drive 
the filtrated ascites to the concentration filter. The left- and 
right-side lower pumps are used for driving normal saline to 
the clogged filtration filter and for drainage of waste fluid 
from the upper header part of the filtration filter, respectively 
(Figure 4B).
Various safety measures such as alarm systems, support 
information systems, safety structures, and safety func-
tions are implemented in M-CART (Table 2). With the 
leak check function, the leak of the hollow fiber can be 
checked with high accuracy. M-CART can detect human 
errors such as the incomplete connection of pressure lines, 
F I G U R E  2  Structure and motions of the multi-ring-type roller pump unit (A) and equipment of M-CART (B). The multi-ring-type roller 
pump unit is composed of roller heads each equipped with a one-way clutch. Roller heads turn according to the direction of the rotation and the 
roller head that does not turn is referred to as the clamp. M-CART is equipped with two multi-ring-type roller pump units. Each pump is equipped 
with an upper clockwise-rotation roller head and a lower counterclockwise-rotation roller head 
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improper mounting of the roller pump tubes, improper 
closing of the two pump covers or the clamp cover, and 
incorrect opening/closing of the manual tube clamps. In 
order to completely attach the tube to the electric clamp, 
a new mechanism (clamp cover) was introduced in which 
the tube was attached to the groove of the clamp cover and 
the tube was attached to the clamp by closing the cover 
(Figure 2B). A snap-in type filter holder was newly devel-
oped instead of the conventional clip type to reduce the 
risk of mixing-up between the filtration and concentration 
filters with the same shape of tube joints (Figure 2B). This 
new type of filter holder takes advantage of the fact that 
only one type of filtration filter (AHF-MO, Asahi Kasei 
Medical Co. Ltd., Tokyo, Japan) and one type of concen-
tration filter (AHF-UP, Asahi Kasei Medical Co. Ltd.) are 
sold, and the outer diameters of these two columns are dif-
ferent (AHF-MO, 55 mm; AHF-UP, 38 mm).
Priming and ascites processing can be performed safely 
by monitoring the transmembrane pressure (TMP) of the 
filtration filter and entrance pressure of the concentration 
filter (Figure 4). The reference pressure value of the filtra-
tion and concentration filters is 500 mm Hg. An excessive 
increase in TMP in filters will cause breakage of hollow 
fibers. In M-CART, automatic washing of clogged filtration 
filter is performed to prevent the breakage of the hollow fi-
bers of the filtration filter or hemolysis of red blood cells in 
bloody ascites. The filtration and concentration process was 
temporarily discontinued when the TMP increased to higher 
than the setpoint by clogging of the filtration filter. The two 
multi-ring-type roller pumps were turned to the opposite 
direction and washing of the filtration filter with normal sa-
line was performed automatically. Clogging of the header 






Structural equipment Roller pump Pump unit 3 2
Roller head 3 4
Motor 3 2
Electric clamp 6 2
Pressure monitor 6 3
Touch panel 1 1
Automatic processing I. Priming 1. Leak check and washing A A
II. Filtration and 
concentration
2. Filtration and concentration A A
3. Washing of clogged filtration filter with 
normal saline
A A
4. Self-regulation of the concentration ratio A A
5. Re-concentrationa Not A
III. Finishing 6. Collection of the ascites in the circuit and 
filters
A A
Type of tube circuit set for CART equipment Panel type Tube holder-type
Abbreviations: A, available; Not, not available.
aOptional function that can be selected by the operator. 
F I G U R E  3  Representative photograph of ascites processing 
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part on the entrance side was resolved by draining the fluids 
in two directions, the entrance side and opposite side, while 
washing the filtration filter (Two-way drainage washing). 
Self-regulation of the concentration ratio is also performed 
to prevent the breakage of the hollow fibers of the concen-
tration filter and to concentrate ascites at a concentration 
ratio as close as possible to the set value. The concentration 
ratio reduces automatically when the entrance pressure of 
the concentration filter increases to higher than the upper 
limit of the setpoint by clogging of the concentration filter 
and the concentration ratio increases automatically when 
the entrance pressure decreases below the lower limit of 
the setpoint. Re-concentration can optionally be conducted 
when there is a large volume of processed ascites (Figure 
4C).
2.4 | Tube holder-type circuit set for 
M-CART
We developed a tube holder-type circuit set for M-CART 
based on human engineering (Figure 5). Two tube circuits 
for the bilateral roller pump were stored in separate bags 
(Figure 5A). Two tube holders were hung on the hooks in 
two poles at the beginning of the circuit setting. Tips of tubes 
were lined up in order of connection from the left side to the 
right side in the two tube holders (Figure 5B,C). We devel-
oped a pump tube guide attached to a circuit tube and loaded 
M-CART with a slide stator structure where a pusher block 
can be moved by opening and shutting off the pump cover so 
that a double tube could be attached to a roller pump easily 
and accurately (Figure 5D).
2.5 | Usability evaluation of the priming  
process
The usability of the priming process of M-CART was 
evaluated by six clinical engineers with no experience 
using M-CART. They had experienced using other types 
of the CART system more than 10 times. After watching 
a 15-minute video orientation about the priming protocol 
and after receiving the priming protocol document, the par-
ticipant worked on priming alone. The total priming time 
(the time from the equipment was switched on until cir-
cuit washing was accomplished) and actual working time 
(the amount of time the clinical engineer spent standing in 
front of M-CART) were measured (Figure 6). The success 
rate (which refers to the completion of the priming process 
alone) was evaluated. Using a questionnaire, the satisfac-
tion about (a) ease of use, (b) simplicity of the operation, 
(c) working time, (d) safety, (e) ease of learning (operation 
can be easily understood), (f) ease of mastering the proce-
dure (operation is easy to memorize), (g) tube holder, and 
(h) pump tube guide was evaluated using a visual analog 
scale.18
F I G U R E  4  Circuit of M-CART. The left-side upper roller pump located between the filtration and concentration filters in the tube circuit 
produces negative pressure to drive the original ascites to the filtration filter and positive pressure to drive the filtrated ascites to the concentration 
filter. Ascites is filtrated from inside the hollow fibers to outside in the filtration filter (A). The filtration and concentration processing is 
temporarily discontinued by the rotational axis of two multi-ring-type roller pumps turning in the opposite direction when the TMP increased to 
higher than the set point by clogging of the filtration filter. The clogging substances in the filtration filter are removed from the lumen and pores of 
the hollow fibers, and header parts on both sides by infusing normal saline from the outside to the inside of the hollow fibers and draining the fluids 
in two directions (two-way drainage washing) (B). Optional re-concentration can be conducted when there is a large volume of processed ascites is 
processed (C). P1-3, pressure monitor 
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2.6 | Clinical evaluation
At Tokushima University Hospital and five affiliated 
hospitals, 41 sessions of standard CART using M-CART 
were performed in 17 patients with refractory ascites from 
September 2018 to April 2019. Filtration filter (AHF-MO) 
and concentration filter (AHF-UP) were used for ascites 
filtration and concentration, and the filtration flow rate was 
set at 50 mL/min. The ascites processing time (the time 
from the beginning of the connection of the original ascites 
bag to the tube circuit until the end of ascites processing), 
the standard operation time for the preparation of the fol-
lowing automatic process or the completion of ascites 
processing, the setting change or suspension time, and the 
response time to alarms and support information were cal-
culated by analyzing the M-CART operation logs (Figure 
7). The automatic processing time was calculated by sub-
tracting the standard operating time, the setting change or 
suspension time, and the response time to alarms or sup-
port information from the ascites processing time. A series 
T A B L E  2  Safety measures of the CART systems
Safety measure CART system
Alarm system: 1-4
Support information system: 5
Safety structure and safety function: 6
Process M-CART Conventional 
equipment with 
the mode for 
CART
Other method
1. Detection of equipment error
(1) System error of the equipment I A A A Not
2. Detection of filter error
(2) Leak of filtration filter I A A Notc
3. Detection of a tube circuit setting error
(3) Incomplete connection of the pressure line I A Not Not
(4) Incomplete mounting of the pump tubing I A Not Not
(5) Cover open (clamp cover/pump cover) I/II/III A A A Not
4. Detection of abnormal processing status
(6) Tube clampa (open/close) I/II/III A A A Not
(7) Abnormal pump rotation I/II/III A Not Not
(8) Abnormal pressure (P1/P2/P3/TMP) I/II/III A A A Not
5. Support information
(9) Bag empty (original ascites) II A A A Not
(10) Bag exchange (processed ascites) II A Not Not
(11) Bag exchange (drained waste fluid/filtrated waste fluid) II A Not Not
(12) Preparation for clogged filtration filter washing II A Not Not
(13) Achieve target process I/II/III A A Not
6. Safety structure and safety function
(14) Touch panel: for procedure guidance I/II/III A A A Not
(15) Snap-in type filter holder: to prevent mixed-up incident I A Not Not
(16) Clamp cover: to prevent incomplete tubing attachment I A Not Not
(17) Pump cover lock structure: to prevent incidental opening I/II/III A Not Not
(18) Tube holder: to keep connecting tips clean I A Not Not
(19) Pump tube guide: to set pump tubes accurately I A Not Not  
(20) Closed-circuit tubing set: to prevent contamination I/II/III A A Not
(21) Automatic washingb of clogged filtration filter and self-
regulation of the concentration ratio
II/III A Not Not
Abbreviations: A, available; I priming; II, filtration and concentration; III, finishing (collection of the ascites in the circuit and filters); Not, not available; P1, pre-
filtration filter pressure; P2, post-filtration filter pressure; P3, pre-concentration filter pressure; TMP, transmembrane pressure of the filtration filter.
aOriginal ascites line, re-concentration line, or normal saline line. 
bTwo-way drainage washing. 
cPerformed manually. 
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of responses to the alarms and support information were 
counted as one response and the time from the beginning 
of the first response to the end of the last response was cal-
culated as one response time. The initial preparation time 
(connection of the original ascites bag and input of set val-
ues), setting change time, and processing completion time 
(pressing the completion button) were added to the ascites 
processing time as 1 minute, 20 seconds, and 10 seconds, 
respectively. The condition of filtration and concentra-
tion (frequencies of automatic washing of clogged filtra-
tion filter and self-regulation of the concentration ratio; the 
number of automatic washing of clogged filtration filter 
performed in one session), weight, and characteristic (spe-
cific gravity, protein concentration, albumin concentration, 
F I G U R E  5  Setting of the tube holder-type circuit set. Two tube circuits for the bilateral roller pump were stored in separate bags (A). The 
tips of the tubes were lined up in order of connection from the left side to the right side in the two tube holders (B) and hung on the hooks in two 
poles (C). The slide stator structure, which moves the pusher block back and forth when the pump cover opens and closes, and pump tube guide aid 
in the quick and accurate setting of the double pump tubes to the multi-ring-type roller pump unit (D) 














Front view Top view
Hole for the hook
Hook
Setting of the double pump tube





F I G U R E  6  Comparison of the priming process. In M-CART, a circuit set-wearing process is performed at the beginning of the priming 
process, and a subsequent leak check and washing are automatically performed. Therefore, the actual working time has been reduced to less than 
half that of the conventional CART equipment without the mode for CART. *At the end of the step, replacement with heparinized normal saline 
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and immunoglobulin G [IgG] concentration) of the original 
and processed ascites were evaluated. The recovery rate 
was calculated as follows:
Data about drugs used (anticoagulant, steroid, and anti-
pyretics) and adverse events associated with the CART pro-
cedure were obtained. This study was approved by the Ethical 
Review Board of Tokushima University Hospital (3182-1) 
and affiliated hospitals.
2.7 | Statistical analysis
The data were expressed as mean ± standard deviation (SD). 
The Mann–Whitney U test and χ2 test were used for the 
analysis of data. A P value of <0.05 was considered signifi-
cant. Statistical analyses were performed by XLSTAT 2016 
(Addinsoft Inc., NY, USA).
3 |  RESULTS
3.1 | Usability evaluation of the priming 
process
The number of years that the participants worked as a clini-
cal engineer and their years of experience performing blood 
purification duties such as hemodialysis were 12.3  ±  6.5 
years and 10.8 ± 6.2 years, respectively. All the participants 
completed the priming process without any help. The actual 
working and priming times were 11.6  ±  1.5 minutes and 
25.0  ±  1.6 minutes, respectively (Figure 8A). With regard 
to its usability, the average satisfaction rates of all the items 
were >70% (Figure 8B).
3.2 | Clinical evaluation
Forty-one sessions of standard CART were performed in 17 
patients with refractory ascites using M-CART (Table 3). Of 
them, nine had cancer (3, gastric cancer; 2, ovarian cancer; 
1, ovarian granulosa cell tumor; 1, colorectal cancer; 1, bile 
duct cancer; and 1, gallbladder cancer) and eight had liver 
cirrhosis. Twenty-two sessions of CART were performed in 
patients with malignant ascites and 19 sessions in those with 
hepatic ascites. The total amount of ascites was processed 
in all the sessions without any trouble. The weights of the 
collected and processed ascites were 4494  ±  2055 g and 
560 ± 188 g, respectively, and the concentration ratio was 
8.0 ± 2.5.
The package insert of the filtration filter states that ascites 
treatment should be performed at a flow rate of ≤3000 mL/h 
to prevent fever.4,17 For this reason, in this study, ascites pro-
cessing was performed at a flow rate of 50 mL/min except for 
one case in which the processing speed was increased from 
50 to 70 mL/min during the treatment of 9070 g of hepatic 
ascites. The mean ascites processing time was 112.5 ± 49.9 
minutes (range: 48.6-267.4 minutes) and a 106.5-minutes 
(95.2%) ascites processing was performed automatically 
(Figure 9). The operator responded to alarms or support in-
formation at a mean of 3.2 ± 3.8 times (range: 0-15 times; 
3.1 ± 4.9 minutes, 2.1 ± 2.7% of ascites processing time). No 
significant difference was found between the malignant and 
hepatic ascites in the ascites processing time and the number 
of responses to alarms or support information. Human errors 
related to ascites processing were detected by M-CART at 
an average of 0.4 times per session (2 times/41 sessions, im-
proper closing of the pump or clamp cover; 17 times/41 ses-
sions, incorrect opening/closing of manual tube clamps) and 
were appropriately addressed by the operator.
Recovery rate (%) = (processed ascitic concentration × processed ascitic weight ∕ processed ascitic specific gravity)
∕(original ascitic concentration × original ascitic weight ∕ original ascitic specific gravity) ×100
F I G U R E  7  Ascites processing procedure in M-CART. Re-concentration (II-2) is an optional process. Collection 1, ascites collection from 
the filtration filter; Collection 2, ascites collection from the concentration filter
II.  Filtration and  concentration III. Finishing 
Preparation / Start
Response to alarm  
Filtration and 
concentration
Collection 1, 2 or 
Collection 2 
Preparation / Start
Response to alarm 
Collection 1
Preparation / Start
Response to alarm 
Re-concentration
Preparation / Start
Response to alarm 
II-1. Standard process II-2. Optional re-concentration






Response to alarms or
support information
Completion
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One washing of the clogged filtration filter took approx-
imately 4 minutes and the number of washings and washing 
times per session were 0.5 ± 0.9 times (range: 0-4 times) and 
2.0  ±  3.7 minutes (range: 0-16 minutes), respectively. The 
frequency of automatic washing of the filtration filter was 
31.7%; the frequencies of automatic washing for malignant 
ascites and hepatic ascites were 50.0% and 10.5%, respec-
tively (Table 3). The frequency of self-regulation of concen-
tration ratio was 53.7% and those for malignant and hepatic 
ascites were 90.9% and 10.5%, respectively. The frequency of 
re-concentration was 14.6% (22.7%, malignant ascites; 5.3%, 
hepatic ascites).
The concentrations of protein, albumin, and IgG were 
significantly higher in malignant ascites than in hepatic as-
cites (Table 4). The recovery rates of protein, albumin, and 
IgG were 72.9 ± 10.9%, 72.9 ± 10.5%, and 71.2 ± 10.4%, 
respectively. The total doses of protein, albumin, and 
IgG were 65.9 ± 41.9 g, 34.9 ± 23.2 g, and 13.2 ± 9.4 g, 
respectively.
The options for the drugs (anticoagulants, steroids, and 
antipyretics) used during CART were determined by the 
treating physicians. As anticoagulant, low-molecular-weight 
heparin (2000 units/bag) was administered to the collected 
ascites at a frequency of 19.5%. Low-molecular-weight hep-
arin was administered to all eight collected malignant ascites 
in one hospital and to seven of the nine malignant ascites in 
another hospital, and no anticoagulant was administered in 
the other four hospitals. Steroids were administered in 38 of 
the 41 sessions (92.7%) before processed ascites infusion to 
prevent fever (Table 5).
The body temperature increased by 0.53  ±  0.58°C 
(malignant ascites, 0.60  ±  0.67°C; hepatic ascites, 
0.45 ± 0.46°C). Antipyretic was administered in four ses-
sions (two sessions, acetaminophen 1000 mg; one session, 
F I G U R E  8  Priming time (A), and 
usability of the priming process and circuit 
set-wearing aids (B). Values are expressed 











































































T A B L E  3  Characteristics of ascites and automatic processing of M-CART
Primary diagnosis
Number of 
sessions Weight of original ascites (g)
Automatic processing (%)
Washing of clogged 
filtration filter
Self-regulation of the 
concentration ratio
Malignancy 22 (53.7%) 3984 ± 1642 (1760-6840) 50.0 90.9
Gastric cancer 10 (24.4%) 3126 ± 1490 (1760-6840) 20.0 100.0
Ovarian granulosa cell tumor 6 (14.6%) 4858 ± 1262 (2910-6160) 100.0 100.0
Ovarian cancer 2 (4.9%) 5820 ± 71 (5770-5870) 100.0 100.0
Colon cancer 2 (4.9%) 3595 ± 2468 (1850-5340) 50.0 100.0
Bile duct cancer 1 (2.4%) 2890 0 0
Gallbladder cancer 1 (2.4%) 5520 0 0
Liver cirrhosis 19 (46.3%) 5085 ± 2356 (1680-11210) 10.5 10.5
Total 41 4494 ± 2055 (1680-11210) 31.7 53.7
Note: Values are expressed as mean ± standard deviation (minimum–maximum).
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acetaminophen 400 mg; one session, celecoxib 100 mg) and 
was effective. Adverse events occurred in 24.4% (10/41) 
of the sessions. A body temperature of ≥38.0°C and 1°C 
increase from the pre-treatment level, which is the defini-
tion of fever by the Japan Society of Transfusion Medicine 
and Cell Therapy,19 were observed in 17.1% of the sessions 
(7/41; four sessions, ovarian granulosa cell tumor; one ses-
sion, gastric cancer; two sessions, liver cirrhosis). Other ad-
verse events included chest pain (1 session) during drainage 
of ascites; chills (2 sessions) and dyspnea (1 session) during 
reinfusion; and dyspnea and palpitation (1 session) after re-
infusion. However, no other adverse events required clinical 
response or no severe adverse events were observed, and the 
patient fully recovered from the events at least by the next 
morning.
4 |  DISCUSSION
We built a consortium for medical-engineering collaboration 
and developed a compact and automatic CART specialized 
equipment (M-CART) using newly developed multi-ring-
type roller pump units. M-CART was approved under the 
Japanese regulations in 2018.
The M-CART has some advantages compared with other 
equipment for CART. It primarily allows the processing of 
a large quantity of ascites without the constant assistance of 
an operator. When using an equipment without the mode for 
CART, the constant assistance of an operator for ascites pro-
cessing was required. However, in M-CART, the operation 
time by the operator was shortened by <5% of the ascites 
processing time, and the ascites processing of the total dose 
was possible in all the cases. This shortening of the work-
ing time was enabled by automatic processing functions es-
pecially automatic washing of clogged filtration filter with 
normal saline and self-regulation of the concentration ratio. 
The response to filtration filter clogging in the conventional 
multi-purpose blood processing equipment with the mode for 
CART was the reduction of filtration flow rate or drainage 
of clogging substances on the side opposite to the ascites en-
trance side. In some cases, the entire amount of ascites could 
not be processed.6,15 However, in M-CART, removal of the 
clogging substances from the lumen, pores of the hollow fi-
bers, and header parts on both sides was performed by infus-
ing normal saline from the outside to the inside of the hollow 
fibers and draining the fluids in two directions (Figure 4B and 
10). Such powerful washing and self-regulation functions of 
the concentration ratio had made the processing of the entire 
amount of ascites possible in all cases in our clinical evalua-
tion. In particular, even in malignant ascites with high viscos-
ity due to ovarian tumor, the entire amount of ascites could 
be treated by repeatedly washing the clogged filtration filter 
and self-regulation of the concentration ratio. Since the main 
target of CART is changing from hepatic ascites to malignant 
ascites, these measures for filter clogging will become more 
important.
As a second advantage, various safety measures such as 
alarm systems, support information systems, safety struc-
tures, and safety functions are implemented in M-CART 
(Table 2). The most important thing in safety management 
during ascites processing is to prevent harmful substances 
such as bacteria and cancer cells from being mixed into the 
processed ascites due to the breakage of the hollow fiber in 
the filtration filter. Washing a clogged filtration filter using a 
syringe carries a risk of damage to the hollow fiber by apply-
ing pressure higher than the tolerable pressure of 500 mm Hg 
in order to wash out the clogging substances by applying suf-
ficient pressure. M-CART can prevent TMPs higher than the 
set value from being applied to the hollow fibers of the filtra-
tion or concentration filters from the start of priming to the 
end of ascites processing. Snap-in type filter holder, pump 
tube guide, and clamp cover, respectively, prevent incidents 
F I G U R E  9  Ascites processing time of the total sessions, malignant ascites, and hepatic ascites. Approximately 95% of ascites processing was 
performed automatically. No significant differences were observed in the ascites processing time and rates of the standard operation and response to 
alarms or support information between the malignant and hepatic ascites. Values are expressed as mean ± standard deviation
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of mixing up between the filtration and concentration filters, 
incorrect pump tube installation, and incomplete mounting 
of clamp tubes. In addition, human errors such as the incom-
plete connection of the pressure lines, opening of the pump 
or clamp cover, and forgetting to close or open the manual 
clamps are detected. Warnings are given by sound and light, 
and the countermeasures are displayed on the touch panel.
As a third advantage, the M-CART is compact and light-
weight. Therefore, the operator can transfer the M-CART to 
any area and can treat ascites simultaneously, while perform-
ing another work. It is also possible to treat ascites at the bed-
side. The multi-ring-type roller pump unit, which is equipped 
with a one-way clutch, is a newly developed pump unit. 
The number of motors and electric clamps can be reduced 
through this pump unit. Equipped with two multi-ring-type 
roller pump units, it became possible to perform all automatic 
processes with two motors and two electric clamps.
Another advantage is that the priming operation of 
M-CART is simple and easy. In M-CART, the procedure from 
priming to completion of processing is displayed on a touch 
panel. Additionally, a circuit set wearing process is performed 
at the beginning of the priming process, and subsequent leak 
check and washing are automatically performed (Figure 6). 
Therefore, the operator can leave M-CART in the second half 
of the priming process (leak check and washing the circuit) and 
the actual working time has been reduced to less than half that 
of the conventional equipment without the mode for CART. 
Based on the results of the survey, the satisfaction rate on the 
use of tube holder was the highest, accounting for 91.0%. The 
high satisfaction rate on the use of this tube holder was because 
the location of the connection tips and the connecting order 
were easy to understand, and the risk of the connecting tips 
falling on the floor and becoming unclean was reduced.
The efficiency of CART for processing ascites is usually 
evaluated based on the recovery rate and dose of protein. Table 
6 shows the past report of recovery rate and dose of protein 
and albumin. Based on our clinical evaluation of M-CART, 
an average of 4494 g of ascites was processed and the total 
amount of ascites was processed in all CART sessions. The 
protein, albumin, and IgG recovery rates (dose) were 72.9%, 
72.9%, and 71.2% (65.9 g, 34.9 g, and 13.2 g), respectively. 
These values were equivalent to or greater than the reported 
T A B L E  4  Ascitic data and procedure of ascites processing of CART
  Total Malignant ascites Hepatic ascites P value
Number of sessions 41 22 (53.7%) 19 (46.3%)  
Original ascites
Weight of ascites (g) 4494 ± 2055 (1680-11210) 3984 ± 1642 (1760-6840) 5085 ± 2356 (1680-11210) 0.191
Total protein (g/dL) 2.4 ± 1.5 (0.3-4.6) 3.6 ± 0.9 (0.8-4.6) 1.0 ± 0.7 (0.3-2.4) <.0001
Albumin (g/dL) 1.3 ± 0.8 (0.2-2.6) 1.9 ± 0.5 (0.3-2.6) 0.5 ± 0.3 (0.2-1.2) <.0001
IgG (mg/dL) 476 ± 309 (76-1370) 656 ± 288 (254-1370) 267 ± 172 (76-680) <.0001
Specific gravity 1.019 ± 0.008 (1.007-1.033) 1.025 ± 0.005 (1.010-1.033) 1.012 ± 0.004 (1.007-1.020) <.0001
Processed ascites
Weight of ascites (g) 560 ± 188 (230-890) 594 ± 207 (300-890) 522 ± 161 (230-880) 0.340
Total protein (g/dL) 12.3 ± 5.8 (2.3-21.0) 16.5 ± 3.3 (5.3-21.0) 7.4 ± 3.9 (2.3-16.3) <.0001
Albumin (g/dL) 6.5 ± 3.3 (1.3-12.9) 8.9 ± 2.1 (2.2-12.9) 3.8 ± 2.0 (1.3-8.4) <.0001
IgG (mg/dL) 2468 ± 1234 (538-5890) 2988 ± 1182 (1150-5890) 1865 ± 1020 (538-3720) 0.005
Specific gravity 1.073 ± 0.031 (1.018-1.120) 1.096 ± 0.017 (1.035-1.120) 1.047 ± 0.022 (1.018-1.092) <.0001
Condition of ascites processing
Concentration ratio 8.0 ± 2.5 (4.6-18.4) 6.6 ± 1.1 (4.6-9.3) 9.6 ± 2.8 (7.3-18.4) <.0001
Re-concentration (%) 14.6 22.7 5.3  
Recovery rate
Total protein (%) 72.9 ± 10.9 (46.8-91.4) 68.7 ± 10.9 (46.8-91.4) 77.9 ± 8.9 (60.7-90.7) 0.009
Albumin (%) 72.9 ± 10.5 (49.9-92.8) 70.3 ± 11.2 (49.9-92.8) 75.9 ± 9.1 (61.1-91.8) 0.126
IgG (%) 71.2 ± 10.4 (42.0-89.1) 67.6 ± 11.3 (42.0-87.5) 75.4 ± 7.5 (64.3-89.1) 0.025
Recovery dose
Total protein (g) 65.9 ± 41.9 (9.1-159.3) 90.2 ± 39.0 (34.3-159.3) 37.9 ± 24.2 (9.1-86.6) <.0001
Albumin (g) 34.9 ± 23.2 (5.0-91.4) 48.5 ± 21.8 (14.2-91.4) 19.3 ± 12.8 (5.0-44.6) <.0001
IgG (g) 13.2 ± 9.4 (1.9-47.4) 16.6 ± 10.7 (4.1-47.4) 9.3 ± 5.8 (1.9-20.8) 0.013
Note: Values are expressed as mean ± standard deviation (minimum–maximum).
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T A B L E  5  Steroid premedication and frequency of fever
Primary diagnosis (number of 
sessions)
Premedication (mg) BT
PSL MPL HYD None Fever Increased BT (°C)
Malignancy (22)         5/22 (22.7%) 0.60 ± 0.67  
(−0.4 to 2.3)
Gastric cancer (4) 30       1/4 (25.0%) 0.78 ± 1.04  
(0-2.3)
Gastric cancer (6)   20a     0/6 0.15 ± 0.44  
(−0.4 to 0.9)
Ovarian granulosa cell tumor (6) 30       4/6 (66.7%) 1.00 ± 0.67 
(0.1-1.6)
Ovarian cancer (1) 30       0/1 1.0
Ovarian cancer (1)       None 0/1 0.7
Colon cancer (1)   20a     0/1 0.5
Colon cancer (1)     125   0/1 0.4
Bile duct cancer (1)   40     0/1 0.6
Gallbladder cancer (1)   20a     0/1 0
Liver cirrhosis (19)         2/19 (10.5%) 0.45 ± 0.46  
(−0.4 to 1.7)
Liver cirrhosis (11)   40     1/11 (9.1%) 0.28 ± 0.39  
(−0.4 to 1.2)
Liver cirrhosis (1)     500   0/1 0.9
Liver cirrhosis (5)     200   0/5 0.44 ± 0.21 
(0.1-0.6)
Liver cirrhosis (2)       None 1/2 (50.0%) 1.15 ± 0.78 
(0.6-1.7)
Total (41)         7/41 (17.1%) 0.53 ± 0.58  
(−0.4 to 2.3)
Note: Fever was defined as a body temperature of ≥38.0°C and a 1°C increase from the pretreatment level. Values are expressed as mean ± standard deviation 
(minimum–maximum).
Abbreviations: BT, body temperature; HYD, hydrocortisone; MPL, methylprednisolone; PSL, prednisolone.
aCombination with 50 mg of flurbiprofen axetil. 
F I G U R E  1 0  Representative transition of the TMP of the filtration filter in the case of filter washing (A) and the aggregate (circled part) of 
the header part on the entrance side of the filtration filter, which was drained into the waste fluid bag by two-way drainage washing (B). M-CART 
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levels.2,6-10,13-16,20-25 The protein recovery rate decreases due to 
the following causes: (a) discontinuation of ascites processing 
due to clogging of the filtration or concentration filters; (b) loss 
of remaining ascites in the filters and circuit after ascites pro-
cessing is completed; (c) loss of ascites due to washing of the 
filtration filter; and (d) protein adsorption to filter membrane. 
By M-CART, the total amount of ascites can be processed by 
automatic washing of clogged filtration filter and self-regu-
lation of the concentration ratio. Furthermore, M-CART is 
equipped with an ascites collection function at the end of asci-
tes processing to improve the recovery rate (Figure 7). When 
the TMP of the filtration filter exceeded 300 mm Hg, auto-
matic washing with 900 mL of normal saline was performed 
in our clinical evaluations. The average number of automatic 
washings with normal saline performed in one session was 0.5 
times (0.9 times, malignant ascites; 0.1 times, hepatic ascites). 
Washing of the filtration filter with normal saline decreases 
the recovery rate as the ascites fluid in the filter is discarded. 
However, if the processing is discontinued without washing, 
the recovery rate will also decrease. Therefore, optimization 
of the timing of filtration filter washing and the washing tech-
nique used should be considered in further studies.
Generally, the most problematic adverse event in CART 
is fever. The degree of fever is thought to be affected by the 
patient’s original disease and condition, ascitic cytokine con-
centration, prophylactic administration of antipyretic drugs, 
and ascites processing speed. In the CART in which posi-
tive pressure-type filtration using a drop-type method or a 
roller pump equipment was performed, fever appeared in 
10.5% of the sessions.6 In the CART in which positive pres-
sure-type filtration from the outside of the hollow fibers to 
the inside using a roller pump equipment was conducted at 
a flow rate of 100 mL/min, steroid was administered in all 
sessions prophylactically, and the elevation of body tempera-
ture was 0.5 ± 0.6°C.15 In the DC-CART in which drop-type 
filtration from the outside of the hollow fibers to the inside 
was performed, a steroid was administered in 56% of the 
sessions prophylactically, and elevation of body temperature 
to >38°C appeared in 16.4% of the sessions.16 The negative 
pressure-type filtration method using a roller pump was lo-
cated after a filtration filter was adapted in M-CART to pre-
vent the risk of the cell components of the ascites producing 
causative agents of the fever by the mechanical stimulation of 
the roller pump. In this study, steroids were administered pro-
phylactically in 92.7% of the sessions, ascites was processed 
at a flow rate of 50 mL/min, and fever occurred in 17.1% of 
the CART sessions and 23.5% of the patients (4/17) and the 
degree of increase in body temperature was 0.53 ± 0.58°C. 
However, the increase in body temperature disappeared at 
least in the next morning. Fever and other side reactions that 
consisted of the problem clinically were not found and the 
CART using M-CART was thought to be safe similarly to 
the conventional CART methods. Further studies about the 
mechanism of fever in CART and the optimization of the as-
cites processing and steroid administration methods for fever 
prevention will be necessary.
M-CART is an equipment approved under the Japanese 
regulations with various safety functions. The Japanese 
Society for Apheresis devised a safety standard for CART 
in 2018.26 In this safety standard, it was indicated that the 
medical equipment approved under the Japanese regula-
tions should be used in accordance with the package insert 
and the use of uncertified equipment such as aspirator or 
syringe is not recommended; the use of specialized equip-
ment with safety functions is recommended following 
the pump-type method. The circuit set for M-CART is a 
closed-circuit system as recommended in the safety stan-
dard of CART to avoid bacterial contamination and retro-
grade infection.
The current ascites processing method adopts the in-
side-out filtration and negative pressure-type method. 
Through further clinical studies and fundamental research, 
the optimization of the ascites processing method (inside-out 
or  outside-in filtration; positive or negative pressure-type; 
and flow rate) should be performed.
5 |  CONCLUSIONS
We developed a novel cell-free and concentrated ascites rein-
fusion therapy specialized equipment (M-CART) with newly 
developed multi-ring-type roller pump units through collabo-
ration between medicine and industry. M-CART is a com-
pact and lightweight CART specialized equipment approved 
under the Japanese regulations. This equipment has various 
safety measures and automatic processing functions such as 
automatic washing of clogged filtration filter using normal 
saline and self-regulation of the concentration ratio, so that 
M-CART can safely and easily process a large quantity of 
ascites without the constant assistance of an operator.
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